


**16<sup>th</sup> · 17<sup>th</sup>**  
**February 2023**



## **José Enrique Alés Martínez**

Centro de Patología de la Mama - Fundación Tejerina, Madrid, Spain

Dr. Alés-Martínez is currently the Director of Investigation at the Centro de Patología de la Mama-Fundación Tejerina in Madrid, Spain. From 1980 to 1986 he had his clinical training and residency in Hospital Puerta de Hierro in Madrid, and then from 1986 to 1989 he was a Wilmot Fellow at Strong Memorial Cancer Center, Rochester, NY where he worked on cellular activation mechanisms and apoptosis in tumor models, research that continued at the Center for Molecular Biology in Madrid, Spain. In the following years he held clinical research positions in medical departments of pharmaceutical laboratories, being responsible for the design and final analysis of clinical trials in breast, lung and colorectal cancer. Later, Dr. Alés was an Associate Oncologist and director of the Clinical Research Program in Hospital Ruber Internacional in Madrid. In 2010 he was appointed Head of Oncology at Hospital Nuestra Señora de Sonsoles in Ávila, Spain, where he stayed until December 2022. He has been principal investigator or co-investigator in over 120 clinical trials and published original basic and clinical research articles in peer-reviewed journal, review articles and book chapters. He has served in the Steering Committee of the MAP.3 trial on Breast cancer chemoprevention. Dr. Alés is currently a member of the Steering Board of the Spanish Group of Investigation in Breast Cancer (GEICAM), and belong to ASCO, ESMO, SEOM and other scientific associations. He has served as member of different Ethics and Research Committees. His main clinical and research interest is breast cancer and its prevention, including hereditary cancer. He is also interested in the manipulation of the immune system for cancer treatment and prevention and the use of imaging to predict and analyze the response to treatments, particularly in breast cancer.

*Innovation  
in Breast Cancer*

*IBC 2023*